ImpediMed Secures $15m Growth Capital Funding

New round will help fuel commercialization efforts in support of ImpediMed's platform technology for the detection and monitoring of lymphedema.CARLSBAD, Calif., Feb. 7, 2025 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, today announced an agreement for a five-year $15 million growth capital facility with SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage com ...